Herpes simplex type 2 virus deleted in glycoprotein D protects against vaginal, skin and neural disease

eLife

Volumn 2015, Issue 4, 2015, Pages 1-18

  Petro, Christopher ^a   González, Pablo A ^a,b   Cheshenko, Natalia ^a   Jandl, Thomas ^a   Khajoueinejad, Nazanin ^a   Bénard, Angèle ^a   Sengupta, Mayami ^a   Herold, Betsy C ^a   Jacobs, William R ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN D; HERPES SIMPLEX VACCINE; MEDROXYPROGESTERONE;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DETECTION; ARTICLE; CELL MEDIATED CYTOTOXICITY; CONTROLLED STUDY; CYTOTOXICITY ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; MOUSE; NEUROLOGIC DISEASE; NONHUMAN; PASSIVE IMMUNIZATION; POLYMERASE CHAIN REACTION; SKIN DISEASE; T LYMPHOCYTE; VAGINA DISEASE; VIRUS DETECTION; VIRUS NEUTRALIZATION; VIRUS REACTIVATION; WESTERN BLOTTING;

EID: 84946182178     PISSN: None     EISSN: 2050084X     Source Type: Journal    
DOI: 10.7554/eLife.06054.001     Document Type: Article

References (59)

1. Aubert M, Yoon M, Sloan DD, Spear PG, Jerome KR. 2009. The virological synapse facilitates herpes simplex virus entry into T cells. Journal of Virology 83:6171–6183. doi: 10.1128/JVI.02163-08.
2. Awasthi S, Belshe RB, Friedman HM. 2014. Better neutralization of herpes simplex virus type 1 (HSV-1) than HSV-2 by antibody from recipients of GlaxoSmithKline HSV-2 glycoprotein D2 subunit vaccine. The Journal of Infectious Diseases 210:5. doi: 10.1093/infdis/jiu177.
3. Belshe RB, Heineman TC, Bernstein DI, Bellamy AR, Ewell M, van der Most R, Deal CD. 2014. Correlate of immune protection against HSV-1 genital disease in vaccinated women. The Journal of Infectious Diseases 209:828–836. doi: 10.1056/NEJMoa1103151.
4. Belshe RB, Leone PA, Bernstein DI, Wald A, Levin MJ, Stapleton JT, Gorfinkel I, Morrow RL, Ewell MG, Stokes-Riner A, Dubin G, Heineman TC, Schulte JM, Deal CDHerpevac Trial for Women. 2012. Efficacy results of a trial of a herpes simplex vaccine. The New England Journal of Medicine 366:34–43. doi: 10.1093/infdis/jit651.
5. Bernstein DI, Aoki FY, Tyring SK, Stanberry LR, St-Pierre C, Shafran SD, Leroux-Roels G, Van Herck K, Bollaerts A, Dubin GGlaxoSmithKline Herpes Vaccine Study Group. 2005. Safety and immunogenicity of glycoprotein D-adjuvant genital herpes vaccine. Clinical Infectious Diseases 40:1271–1281. doi: 10.1086/429240.
6. Bernstein DI, Bellamy AR, Hook EW III, Levin MJ, Wald A, Ewell MG, Wolff PA, Deal CD, Heineman TC, Dubin G, Belshe RB. 2013. Epidemiology, clinical presentation, and antibody response to primary infection with herpes simplex virus type 1 and type 2 in young women. Clinical Infectious Diseases 56:344–351. doi: 10.1093/cid/cis891.
7. Bialuk I, Whitney S, Andresen V, Florese RH, Nacsa J, Cecchinato V, Valeri VW, Heraud JM, Gordon S, Parks RW, Montefiori DC, Venzon D, Demberg T, Guroff MR, Landucci G, Forthal DN, Franchini G. 2011. Vaccine induced antibodies to the first variable loop of human immunodeficiency virus type 1 gp120, mediate antibodydependent virus inhibition in macaques. Vaccine 30:78–94. doi: 10.1016/j.vaccine.2011.10.040.
8. Bonsignori M, Pollara J, Moody MA, Alpert MD, Chen X, Hwang KK, Gilbert PB, Huang Y, Gurley TC, Kozink DM, Marshall DJ, Whitesides JF, Tsao CY, Kaewkungwal J, Nitayaphan S, Pitisuttithum P, Rerks-Ngarm S, Kim JH, Michael NL, Tomaras GD, Montefiori DC, Lewis GK, DeVico A, Evans DT, Ferrari G, Liao HX, Haynes BF. 2012. Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. Journal of Virology 86:11521–11532. doi: 10.1128/JVI.01023-12.
9. Boursnell ME, Entwisle C, Blakeley D, Roberts C, Duncan IA, Chisholm SE, Martin GM, Jennings R, Ni Challanain D, Sobek I, Inglis SC, McLean CS. 1997. A genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 disease. The Journal of Infectious Diseases 175:16–25. doi: 10.1093/infdis/175.1.16.
10. Brown SM, Ritchie DA, Subak-Sharpe JH. 1973. Genetic studies with herpes simplex virus type 1. The isolation of temperature-sensitive mutants, their arrangement into complementation groups and recombination analysis leading to a linkage map. The Journal of General Virology 18:329–346. doi: 10.1099/0022-1317-18-3-329.
11. Cairns TM, Huang ZY, Whitbeck JC, Ponce de Leon M, Lou H, Wald A, Krummenacher C, Eisenberg RJ, Cohen GH. 2014. Dissection of the antibody response against herpes simplex virus glycoproteins in naturally infected humans. Journal of Virology 88:12612–12622. doi: 10.1128/JVI.01930-14.
12. Chen L, Jha P, Stirling B, Sgaier SK, Daid T, Kaul R, Nagelkerke NInternational Studies of HIV/AIDS (ISHA) Investigators. 2007. Sexual risk factors for HIV infection in early and advanced HIV epidemics in sub-Saharan Africa: systematic overview of 68 epidemiological studies. PLOS ONE 2:e1001. doi: 10.1371/journal.pone.0001001.
13. Cheshenko N, Herold BC. 2002. Glycoprotein B plays a predominant role in mediating herpes simplex virus type 2 attachment and is required for entry and cell-to-cell spread. The Journal of General Virology 83: 2247–2255.
14. Cheshenko N, Keller MJ, MasCasullo V, Jarvis GA, Cheng H, John M, Li JH, Hogarty K, Anderson RA, Waller DP, Zaneveld LJ, Profy AT, Klotman ME, Herold BC. 2004. Candidate topical microbicides bind herpes simplex virus glycoprotein B and prevent viral entry and cell-to-cell spread. Antimicrobial Agents and Chemotherapy 48: 2025–2036. doi: 10.1128/AAC.48.6.2025-2036.2004.
15. Cheshenko N, Liu W, Satlin LM, Herold BC. 2007. Multiple receptor interactions trigger release of membrane and intracellular calcium stores critical for herpes simplex virus entry. Molecular Biology of the Cell 18:3119–3130. doi: 10.1091/mbc.E07-01-0062.
16. Cheshenko N, Trepanier JB, Gonzalez PA, Eugenin EA, Jacobs WR Jr, Herold BC. 2014. Herpes simplex virus type 2 glycoprotein H interacts with integrin alphavbeta3 to facilitate viral entry and calcium signaling in human genital tract epithelial cells. Journal of Virology 88:10026–10038. doi: 10.1128/JVI.00725-14.
17. Cheshenko N, Trepanier JB, Stefanidou M, Buckley N, Gonzalez P, Jacobs W, Herold BC. 2013. HSV activates Akt to trigger calcium release and promote viral entry: novel candidate target for treatment and suppression. FASEB Journal 27:2584–2599. doi: 10.1096/fj.12-220285.
18. Corey L, Langenberg AG, Ashley R, Sekulovich RE, Izu AE, Douglas JM Jr, Handsfield HH, Warren T, Marr L, Tyring S, DiCarlo R, Adimora AA, Leone P, Dekker CL, Burke RL, Leong WP, Straus SE. 1999. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. JAMA 282:331–340. doi: 10.1001/jama.282.4.331.
19. Da Costa X, Kramer MF, Zhu J, Brockman MA, Knipe DM. 2000. Construction, phenotypic analysis, and immunogenicity of a UL5/UL29 double deletion mutant of herpes simplex virus 2. Journal of Virology 74: 7963–7971. doi: 10.1128/JVI.74.17.7963-7971.2000.
20. de Bruyn G, Vargas-Cortez M, Warren T, Tyring SK, Fife KH, Lalezari J, Brady RC, Shahmanesh M, Kinghorn G, Beutner KR, Patel R, Drehobl MA, Horner P, Kurtz TO, McDermott S, Wald A, Corey L. 2006. A randomized controlled trial of a replication defective (gH deletion) herpes simplex virus vaccine for the treatment of recurrent genital herpes among immunocompetent subjects. Vaccine 24:914–920. doi: 10.1016/j.vaccine.2005.08.088.
21. Dilillo DJ, Tan GS, Palese P, Ravetch JV. 2014. Broadly neutralizing hemagglutinin stalk-specific antibodies require FcgammaR interactions for protection against influenza virus in vivo. Nature Medicine 20:143–151. doi: 10.1038/nm.3443.
22. Dudek T, Mathews LC, Knipe DM. 2008. Disruption of the U(L)41 gene in the herpes simplex virus 2 dl5-29 mutant increases its immunogenicity and protective capacity in a murine model of genital herpes. Virology 372:165–175. doi: 10.1016/j.virol.2007.10.014.
23. Ejercito PM, Kieff ED, Roizman B. 1968. Characterization of herpes simplex virus strains differing in their effects on social behaviour of infected cells. The Journal of General Virology 2:357–364. doi: 10.1099/0022-1317-2-3-357.
24. Florese RH, Demberg T, Xiao P, Kuller L, Larsen K, Summers LE, Venzon D, Cafaro A, Ensoli B, Robert-Guroff M. 2009. Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines. Journal of Immunology 182: 3718–3727. doi: 10.4049/jimmunol.0803115.
25. Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ. 2006. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 20:73–83. doi: 10.1097/01.aids.0000198081.09337.a7.
26. Goel N, Docherty JJ, Fu MM, Zimmerman DH, Rosenthal KS. 2002. A modification of the epidermal scarification model of herpes simplex virus infection to achieve a reproducible and uniform progression of disease. Journal of Virological Methods 106:153–158. doi: 10.1016/S0166-0934(02)00160-X.
27. Grauwet K, Cantoni C, Parodi M, De Maria A, Devriendt B, Pende D, Moretta L, Vitale M, Favoreel HW. 2014. Modulation of CD112 by the alphaherpesvirus gD protein suppresses DNAM-1-dependent NK cell-mediated lysis of infected cells. Proceedings of the National Academy of Sciences of USA 111:16118–16123. doi: 10.1073/pnas.1409485111.
28. Gray RH, Wawer MJ, Brookmeyer R, Sewankambo NK, Serwadda D, Wabwire-Mangen F, Lutalo T, Li X, vanCott T, Quinn TC Rakai Project Team. 2001. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 357:1149–1153. doi: 10.1016/S0140-6736(00)04331-2.
29. Horowitz R, Aierstuck S, Williams EA, Melby B. 2011. Herpes simplex virus infection in a university health population: clinical manifestations, epidemiology, and implications. Journal of American College Health 59: 69–74. doi: 10.1080/07448481.2010.483711.
30. Hoshino Y, Dalai SK, Wang K, Pesnicak L, Lau TY, Knipe DM, Cohen JI, Straus SE. 2005. Comparative efficacy and immunogenicity of replication-defective, recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs. Journal of Virology 79:410–418. doi: 10.1128/JVI.79.1.410-418.2005.
31. Hoshino Y, Pesnicak L, Dowdell KC, Burbelo PD, Knipe DM, Straus SE, Cohen JI. 2009. Protection from herpes simplex virus (HSV)-2 infection with replication-defective HSV-2 or glycoprotein D2 vaccines in HSV-1- seropositive and HSV-1-seronegative guinea pigs. The Journal of Infectious Diseases 200:1088–1095. doi: 10.1086/605645.
32. Hoshino Y, Pesnicak L, Dowdell KC, Lacayo J, Dudek T, Knipe DM, Straus SE, Cohen JI. 2008. Comparison of immunogenicity and protective efficacy of genital herpes vaccine candidates herpes simplex virus 2 dl5-29 and dl5-29-41L in mice and guinea pigs. Vaccine 26:4034–4040. doi: 10.1016/j.vaccine.2008.05.022.
33. Kaushic C, Ashkar AA, Reid LA, Rosenthal KL. 2003. Progesterone increases susceptibility and decreases immune responses to genital herpes infection. Journal of Virology 77:4558–4565. doi: 10.1128/JVI.77.8.4558-4565.2003.
34. Kohl S, Charlebois ED, Sigouroudinia M, Goldbeck C, Hartog K, Sekulovich RE, Langenberg AG, Burke RL. 2000. Limited antibody-dependent cellular cytotoxicity antibody response induced by a herpes simplex virus type 2 subunit vaccine. The Journal of Infectious Diseases 181:335–339. doi: 10.1086/315208.
35. Kopp SJ, Storti CS, Muller WJ. 2012. Herpes simplex virus-2 glycoprotein interaction with HVEM influences virus-specific recall cellular responses at the mucosa. Clinical & Developmental Immunology 2012:284104. doi: 10.1155/2012/284104.
36. La S, Kim J, Kwon BS, Kwon B. 2002. Herpes simplex virus type 1 glycoprotein D inhibits T-cell proliferation. Molecules and Cells 14:398–403.
37. Leroux-Roels G, Clément F, Vandepapelière P, Fourneau M, Heineman TC, Dubin G. 2013. Immunogenicity and safety of different formulations of an adjuvanted glycoprotein D genital herpes vaccine in healthy adults: a double-blind randomized trial. Human Vaccines & Immunotherapeutics 9:1254–1262. doi: 10.4161/hv.24043.
38. Li Z, Palaniyandi S, Zeng R, Tuo W, Roopenian DC, Zhu X. 2011. Transfer of IgG in the female genital tract by MHC class I-related neonatal Fc receptor (FcRn) confers protective immunity to vaginal infection. Proceedings of the National Academy of Sciences of USA 108:4388–4393. doi: 10.1073/pnas.1012861108.
39. Ligas MW, Johnson DC. 1988. A herpes simplex virus mutant in which glycoprotein D sequences are replaced by beta-galactosidase sequences binds to but is unable to penetrate into cells. Journal of Virology 62:1486–1494.
40. Looker KJ, Garnett GP, Schmid GP. 2008. An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection. Bulletin of the World Health Organization 86:805–812, A. doi: 10.2471/BLT.07.046128.
41. Mertz GJ, Ashley R, Burke RL, Benedetti J, Critchlow C, Jones CC, Corey L. 1990. Double-blind, placebocontrolled trial of a herpes simplex virus type 2 glycoprotein vaccine in persons at high risk for genital herpes infection. The Journal of Infectious Diseases 161:653–660. doi: 10.1093/infdis/161.4.653.
42. Milligan GN, Dudley-McClain KL, Chu CF, Young CG. 2004. Efficacy of genital T cell responses to herpes simplex virus type 2 resulting from immunization of the nasal mucosa. Virology 318:507–515. doi: 10.1016/j.virol.2003.10.010.
43. Morrison LA, Zhu L, Thebeau LG. 2001. Vaccine-induced serum immunoglobin contributes to protection from herpes simplex virus type 2 genital infection in the presence of immune T cells. Journal of Virology 75:1195–1204. doi: 10.1128/JVI.75.3.1195-1204.2001.
44. Myers EW, Miller W. 1988. Optimal alignments in linear space. Computer Applications in the Biosciences 4:11–17.
45. Nixon B, Stefanidou M, Mesquita PM, Fakioglu E, Segarra T, Rohan L, Halford W, Palmer KE, Herold BC. 2013. Griffithsin protects mice from genital herpes by preventing cell-to-cell spread. Journal of Virology 87:6257–6269. doi: 10.1128/JVI.00012-13.
46. Parr EL, Bozzola JJ, Parr MB. 1998. Immunity to vaginal infection by herpes simplex virus type 2 in adult mice: characterization of the immunoglobulins in vaginal mucus. Journal of Reproductive Immunology 38:15–30. doi: 10.1016/S0165-0378(97)00081-8.
47. Parr EL, Parr MB. 1998. Immunoglobulin G, plasma cells, and lymphocytes in the murine vagina after vaginal or parenteral immunization with attenuated herpes simplex virus type 2. Journal of Virology 72:5137–5145.
48. Roberts CM, Pfister JR, Spear SJ. 2003. Increasing proportion of herpes simplex virus type 1 as a cause of genital herpes infection in college students. Sexually Transmitted Diseases 30:797–800. doi: 10.1097/01.OLQ.0000092387.58746.C7.
49. Segarra TJ, Fakioglu E, Cheshenko N, Wilson SS, Mesquita PM, Doncel GF, Herold BC. 2011. Bridging the gap between preclinical and clinical microbicide trials: blind evaluation of candidate gels in murine models of efficacy and safety. PLOS ONE 6:e27675. doi: 10.1371/journal.pone.0027675.
50. Sharma S, Rajasagi NK, Veiga-Parga T, Rouse BT. 2014. Herpes virus entry mediator (HVEM) modulates proliferation and activation of regulatory T cells following HSV-1 infection. Microbes and Infection 16:648–660. doi: 10.1016/j.micinf.2014.06.005.
51. Shin H, Iwasaki A. 2012. A vaccine strategy that protects against genital herpes by establishing local memory T cells. Nature 491:463–467. doi: 10.1038/nature11522.
52. Speck PG, Efstathiou S, Minson AC. 1996. In vivo complementation studies of a glycoprotein H-deleted herpes simplex virus-based vector. The Journal of General Virology 77:2563–2568. doi: 10.1099/0022-1317-77-10-2563.
53. Spector FC, Kern ER, Palmer J, Kaiwar R, Cha TA, Brown P, Spaete RR. 1998. Evaluation of a live attenuated recombinant virus RAV 9395 as a herpes simplex virus type 2 vaccine in guinea pigs. The Journal of Infectious Diseases 177:1143–1154. doi: 10.1086/515278.
54. Stanberry LR, Spruance SL, Cunningham AL, Bernstein DI, Mindel A, Sacks S, Tyring S, Aoki FY, Slaoui M, Denis M, Vandepapeliere P, Dubin G, GlaxoSmithKline Herpes Vaccine Efficacy Study Group 2002. Glycoprotein-Dadjuvant vaccine to prevent genital herpes. The New England Journal of Medicine 347:1652–1661. doi: 10.1056/NEJMoa011915.
55. Stiles KM, Whitbeck JC, Lou H, Cohen GH, Eisenberg RJ, Krummenacher C. 2010. Herpes simplex virus glycoprotein D interferes with binding of herpesvirus entry mediator to its ligands through downregulation and direct competition. Journal of Virology 84:11646–11660. doi: 10.1128/JVI.01550-10.
56. Vicetti Miguel RD, Hendricks RL, Aguirre AJ, Melan MA, Harvey SA, Terry-Allison T, St Leger AJ, Thomson AW, Cherpes TL. 2012. Dendritic cell activation and memory cell development are impaired among mice administered medroxyprogesterone acetate prior to mucosal herpes simplex virus type 1 infection. The Journal of Immunology 189:3449–3461. doi: 10.4049/jimmunol.1103054.
57. Wald A, Link K. 2002. Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. The Journal of Infectious Diseases 185:45–52. doi: 10.1086/338231.
58. Xu F, Sternberg MR, Kottiri BJ, McQuillan GM, Lee FK, Nahmias AJ, Berman SM, Markowitz LE. 2006. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 296:964–973. doi: 10.1001/jama.296.8.964.
59. Zago A, Jogger CR, Spear PG. 2004. Use of herpes simplex virus and pseudorabies virus chimeric glycoprotein D molecules to identify regions critical for membrane fusion. Proceedings of the National Academy of Sciences of USA 101:17498–17503. doi: 10.1073/pnas.0408186101.